Home > Insider Trading > Filing (0001209191-18-053533)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724344	Entasis Therapeutics Holdings Inc.	ETTX	Pharmaceutical Preparations (2834)	1231

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
901832	Plc Astrazeneca	1 Francis Crick Avenue Cambridge X0 CB2 0AA		No	No	Yes	No
928966	Ab Astrazeneca	C/O Astrazeneca Plc 1 Francis Crick Avenue Cambridge X0 CB2 0AA		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-09-28	1,918,185	$0.00	1,918,189	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-09-28	246,666	$15.00	2,164,855	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-09-28	33,499,900	$0.00	1,616,166	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

This number includes 302,019 shares of Common Stock received upon the conversion of the Issuer's Series A Preferred Stock as payment of accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
Each share of Series A Preferred Stock automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.
All of these securities are owned by AstraZeneca AB, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca AB, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any. The principal business address of AstraZeneca AB is SE-151 85 Sodertalje, Sweden.